Request for Covid-19 Impact Assessment of this Report
Vaccination saves lives and improves quality of life. For instance, Polio is an infectious disease caused by poliovirus and causes muscle weakness that results in the inability to move, which further hampers the quality of life. Polio vaccine protects an individual against polio. The vaccine produces antibodies in the bloodstream against the poliovirus. Due to the strong promotion of Polio vaccine in Europe, the World Health Organization in 2002, declared the European Region polio-free.
The countries in the European region are joining forces to eradicate infectious diseases like measles, diphtheria, rubella, pertussis, and others through vaccinations. There are several vaccination programs, campaigns, conferences, being held in the European region in order to raise awareness among the population. For instance, European Immunization Week (EIW) is renowned across the European Region and is celebrated every April to raise awareness of the importance of vaccination for people’s health and well-being. European Centre for Disease Prevention and Control (ECDC) supports the European Immunization Week campaign undertook by WHO/Europe and provides scientific evidence on vaccination.
Furthermore, 38th Euro Global Summit and Expo on Vaccines & Vaccination will be held in June 2020 Frankfurt, Germany. The conference focuses on discussing novel strategies in vaccines and immunology research. The aim of the conference is to encourage quality research and to bring together the world-class researchers, international communities, and industrial heads to discuss the new developments and innovations in the fields of vaccines and immunology.
In 2018, the conjugate vaccines segment held the largest market share of 27.6% of the vaccines market, by type. This segment is also expected to dominate the market in 2027 owing to the advantages offered by the vaccines for diseases such as pneumonia and others. Furthermore, the conjugate vaccines segment is anticipated to witness the significant growth rate during the forecast period, 2019 to 2027.
Europe Vaccines Market by the disease indication was led by the other segments, which has included diseases such as poliomyelitis (polio), measles, mumps, rubella, pneumococcal infections, and others. The other segment has the largest market share in 2018, which accounted for 59.8% and is expected to dominate the market in 2027. Similarly, the vaccines market by the route of administration was led by the injectable segment. Whereas, the market of the vaccines in Europe by the patient type was led by the pediatric segment.
Some of the major primary and secondary sources for vaccines included in the report are Immunization Partners in Europe (IPAP), Food and Drug Administration, World Health Organization, National Polio Surveillance Project (NPSP), European Health Management Association (EHMA), European Centre for Disease Prevention and Control (ECDC), European Immunization Week (EIW) and Others.
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
2. Europe Vaccines Market – Key Takeaways
3. Europe Vaccines Market – Market Landscape
3.1 overview
3.2 Market Segmentation
3.2.1 Europe Vaccines Market – By Technology
3.2.2 Europe Market – By Disease Indication
3.2.3 Europe Vaccines Market – By Route of Administration
3.2.4 Europe Vaccines Market – By Patient Type
3.2.5 Europe Vaccines Market – By Country
3.3 PEST Analysis
4. Europe Vaccines Market - Key Market Dynamics
4.1 Key Market Drivers
4.1.1 Growing Awareness Programs for Vaccination in Europe
4.1.2 Increasing Vaccines Research and Development Activities in Europe.
4.2 Key Market Restraints
4.2.1 Vaccines Hesitancy in the European region.
4.3 Key Market Opportunities
4.3.1 Growing Prevalence of Infectious Diseases
4.4 Future Trends
4.4.1 New Vaccines In Development
4.5 Impact Analysis
5. Vaccines Market – Europe Analysis
5.1 Europe Vaccines Market Revenue Forecasts and Analysis
5.2 Market Positioning
5.3 Performance of Key Players
5.3.1 Sanofi
6. Europe Vaccines Market Analysis – By Technology
6.1 Overview
6.2 Europe Vaccines Market, By Type, 2018 & 2027 (%)
6.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
6.4 Europe Recombinant Vaccines Market
6.4.1 Overview
6.4.2 Europe Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.5 Europe Conjugate Vaccines Market
6.5.1 Overview
6.5.2 Europe Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.6 Europe Live Attenuated Vaccines Market
6.6.1 Overview
6.6.2 Europe Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.7 Europe Inactivated Vaccines Market
6.7.1 Overview
6.7.2 Europe Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.8 Europe Toxoid Vaccines Market
6.8.1 Overview
6.8.2 Europe Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
7. Europe Vaccines Market Analysis – By Disease Indication
7.1 Overview
7.2 Europe Vaccines Market, By Disease Indication, 2018 & 2027 (%)
7.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
7.4 Europe DTP (Diphtheria, Tetanus, And Pertussis) Market
7.4.1 Overview
7.4.2 Europe DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)
7.5 Europe Influenza Market
7.5.1 Overview
7.5.2 Europe Influenza Market Revenue and Forecast to 2027 (US$ Mn)
7.6 Europe Hepatitis Market
7.6.1 Overview
7.6.2 Europe Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)
7.7 Europe Other Diseases Market
7.7.1 Overview
7.7.2 Europe Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)
8. Europe Vaccines Market Analysis – By Route of Administration
8.1 Overview
8.2 Europe Vaccines Market, By Route of Administration, 2018 & 2027 (%)
8.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
8.4 Europe Oral Market
8.4.1 Overview
8.4.2 Europe Oral Market Revenue and Forecast to 2027 (US$ Mn)
8.5 Europe Injectable Market
8.5.1 Overview
8.5.2 Europe Injectable Market Revenue and Forecast to 2027 (US$ Mn)
8.6 Europe Other Routes of Administration Market
8.6.1 Overview
8.6.2 Europe Other Routes of Administration Market Revenue and Forecast to 2027 (US$ Mn)
9. Europe Vaccines Market Analysis – By Patient Type
9.1 Overview
9.2 Europe Vaccines Market, By Patient Type, 2018 & 2027 (%)
9.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
9.4 Europe Pediatric Market
9.4.1 Overview
9.4.2 Europe Pediatric Market Revenue and Forecast to 2027 (US$ Mn)
9.5 Europe Adults Market
9.5.1 Overview
9.5.2 Europe Adults Market Revenue and Forecast to 2027 (US$ Mn)
10. Europe Vaccines Market Revenue And Forecasts To 2027
10.1.1 Europe Vaccines Market Revenue Overview, by Country (2017) (US$ Mn)
10.1.2 Europe Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.4 Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.5 Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.6 Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.7 Europe Vaccines Market Revenue and Forecasts to 2027, By Country (%)
10.1.8 Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.9 Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.9.1 Germany Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.9.2 Germany Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.9.3 Germany Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.9.4 Germany Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.10 UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.11 UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.11.1 UK Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.11.2 UK Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.11.3 UK Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.11.4 UK Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.12 France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.13 France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.13.1 France Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.13.2 France Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.13.3 France Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.13.4 France Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.14 Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.15 Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.15.1 Italy Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.15.2 Italy Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.15.3 Italy Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.15.4 Italy Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
10.1.16 Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.17 Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.17.1 Spain Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
10.1.17.2 Spain Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
10.1.17.3 Spain Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
10.1.17.4 Spain Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11. Vaccines Market –Industry Landscape
11.1 Overview
11.2 Comparative Company Analysis
11.3 Growth Strategies Done by the Companies in the Market, (%)
11.4 Organic Developments
11.4.1 Overview
11.5 Inorganic Developments
11.5.1 Overview
12. Vaccines Market–Key Company Profiles
12.1 Pfizer Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Financial Overview
12.1.4 Product Portfolio
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 GlaxoSmithKline plc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Financial Overview
12.2.4 Product Portfolio
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Merck & Co., Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Financial Overview
12.3.4 Product Portfolio
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sanofi
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Financial Information
12.4.4 Product Portfolio
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Johnson & Johnson Services, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Financial Overview
12.5.4 Product Portfolio
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Panacea Biotic Limited
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Financial Information
12.6.4 Product Portfolio
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Astellas Pharma Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Financial Overview
12.7.4 Product Portfolio
12.7.5 Swot Analysis
12.7.6 Key Developments
12.8 NOVAVAX, INC.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Financial Information
12.8.4 Product Pipeline
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 VBI Vaccines Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Financial Information
12.9.4 Product Portfolio
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 BAVARIAN NORDIC
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Financial Information
12.10.4 Product Pipeline
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
13.3 Methodology
13.3.1 Coverage
13.3.2 Secondary Research
13.3.3 Primary Research
Table 2. Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
Table 3. Europe Vaccines Market Revenue And Forecasts to 2027, By route of administration (US$ Mn)
Table 4. Europe Vaccines Market Revenue And Forecasts to 2027, By patient type (US$ Mn)
Table 5. Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 6. Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
Table 7. Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 8. Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
Table 9. Germany Vaccines Market Revenue And Forecasts To 2027, By Technology (US$ Mn)
Table 10. Germany Vaccines Market Revenue And Forecasts To 2027, By Disease Indication (US$ Mn)
Table 11. Germany Vaccines Market Revenue And Forecasts To 2027, By Route Of Administration (US$ Mn)
Table 12. Germany Vaccines Market Revenue And Forecasts To 2027, By Patient Type (US$ Mn)
Table 13. UK Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 14. UK Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
Table 15. UK Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 16. UK Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
Table 17. France Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 18. France Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
Table 19. France Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 20. France Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
Table 21. Italy Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 22. Italy Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
Table 23. Italy Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 24. Italy Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
Table 25. Spain Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 26. Spain Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
Table 27. Spain Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
Table 28. Spain Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
Table 29. Organic Developments Done By Companies
Table 30. Inorganic Developments Done by Companies
Table 31. Glossary of Terms, Vaccines market
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...